Peptide Atlas · Peptide

TB-500

Analysis of the product sold as TB-500 identified the N-terminally acetylated 17-23 fragment of human thymosin beta 4, Ac-LKKTETQ.

preclinical

What the evidence says

six tiers, never blended

preclinical — animal, cell or mechanistic work — not yet about people

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'TB-500' · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
fact added identity: PubChem CID 62707662: Unii-qhk6Z47gtg, C38H68N10O14, 889.0 g/mol. · 2026-09-27 04:00 · somebody
fact added identity: CAS registry number 885340-08-9. · 2026-09-27 04:00 · somebody
fact added identity: IUPAC name: (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-6-amin · 2026-09-27 04:00 · somebody
fact added summary: Analysis of the product sold as TB-500 identified the N-terminally acetylated 17-23 fragment of human thymosin beta 4, A · 2026-09-27 04:00 · somebody
fact added mechanism: The LKKTETQ sequence lies in thymosin beta 4's central actin-binding domain, and short peptides containing it promoted a · 2026-09-27 04:00 · somebody
citation added pmid 22962027 cited as unknown: Identification of Ac-LKKTETQ in TB-500 by high-resolution mass spectrometry · 2026-09-27 04:00 · somebody
citation added pmid 20179146 cited as preclinical: Review: active sites of thymosin beta 4 in short peptide sequences · 2026-09-27 04:00 · somebody

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.